System and method for evaluating curative effect of traditional Chinese medicine intervened angina pectoris

Abstract

The invention discloses a curative effect evaluation system and method for traditional Chinese medicine intervention of angina pectoris, and belongs to the technical field of medical services, and the system comprises a case collection module which collects information of hospitalized patients with intermingled phlegm and blood stasis syndromes which are clinically diagnosed as UA, and carries out the filing of the information of each patient; the medication mode queue module is used for queuing the filing information of each patient; by adopting a two-way queue research design and depending on a'chest stuffiness and pains special disease library ', grouping is carried out according to a plurality of optimized traditional Chinese medicine medication modes as exposure factors, different medication mode queues are established, retrospective data acquisition and prospective follow-up visit are carried out on all subjects, curative effect evaluation modeling of grouped crowds is carried out, and the curative effect of the subjects is evaluated. The correlation between data generated by different treatment times is fully considered, an evaluation model capable of dynamically evaluating the curative effect of the patient is established, real-time, dynamic and accurate evaluation of the clinical curative effect of the traditional Chinese medicine is realized, and a real-world traditional Chinese medicine evidence-based basis is provided for guiding clinical practice and making health policies.

Description

Technical Field

[0001] The present invention belongs to the field of medical service technology, and in particular relates to a system and method for evaluating the efficacy of traditional Chinese medicine intervention in angina pectoris. Background Art

[0002] Unstable angina (UA) of coronary heart disease can easily develop into acute myocardial infarction or sudden death in a short period of time, and the disease burden is serious. Traditional Chinese medicine has long been used in the clinical treatment of UA due to its significant efficacy, low cost, and low adverse reactions. However, due to the individualized and dynamically changing complex intervention measures of traditional Chinese medicine in the real world of diagnosis and treatment, the classic clinical epidemiology and evidence-based medicine methods cannot fully reflect the true diagnosis and treatment characteristics and clinical efficacy of traditional Chinese medicine. Summary of the invention

[0003] The purpose of the present invention is to solve the above-mentioned problems and to propose a system and method for evaluating the efficacy of Chinese medicine intervention in angina pectoris.

[0004] On the one hand, in order to achieve the above-mentioned purpose, the present invention adopts the following technical scheme: a therapeutic effect evaluation system of traditional Chinese medicine intervention for angina pectoris, comprising:

[0005] The case collection module collects information on hospitalized patients with phlegm-stasis syndrome who are clinically diagnosed with UA and creates files for each patient;

[0006] The medication mode cohort module groups each patient according to their profile information and multiple selected TCM medication modes as exposure factors, and establishes different medication mode cohorts;

[0007] The retrospective collection module collects the patient's medical history characteristics, clinical diagnosis, comorbidities, treatment status, and length of hospital stay;

[0008] The tracking and collection module follows up the patients and collects the primary and secondary outcome indicators;

[0009] The efficacy evaluation module combines the parameters of the tracing collection module and the tracking collection module to establish an efficacy evaluation model.

[0010] As a further description of the above technical solution:

[0011] The density of readmission for cardiovascular-related diseases was the primary outcome indicator, and the density of major adverse cardiovascular events (MACE), the density of all-cause mortality, the scores of the Traditional Chinese Medicine Therapeutic Effect Evaluation Scale for different syndromes of coronary heart disease, the scores of the Seattle Angina Scale (SAQ), and the GRACE score were the secondary outcome indicators.

[0012] As a further description of the above technical solution:

[0013] The tracking and collection module also collects safety indicators, with the incidence of adverse events, liver function, kidney function, and coagulation as safety indicators.

[0014] As a further description of the above technical solution:

[0015] The efficacy evaluation module uses the RNN algorithm to model the efficacy evaluation of grouped populations based on classic multivariate analysis, COX regression, and survival analysis.

[0016] On the other hand, in order to achieve the above-mentioned purpose, the present invention adopts the following method: a method for evaluating the efficacy of Chinese medicine intervention on angina pectoris, comprising the following steps:

[0017] 1) The case collection module collects information on hospitalized patients with phlegm-stasis syndrome clinically diagnosed as UA and creates files for each patient;

[0018] 2) The medication mode cohort module groups each patient according to their profile information and multiple preferred TCM medication modes as exposure factors, and establishes different medication mode cohorts;

[0019] 3) The retrospective collection module collects the patient's medical history characteristics, clinical diagnosis, comorbidities, treatment status, and length of hospital stay;

[0020] 4) The tracking and collection module follows up patients and collects primary and secondary outcome indicators;

[0021] 5) The efficacy evaluation module combines the parameters of the tracing collection module and the tracking collection module to establish an efficacy evaluation model.

[0022] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are:

[0023] In the present invention, by adopting a two-way cohort study design and relying on the "chest pain and heart pain special disease database", groups were made according to multiple preferred TCM medication modes as exposure factors, different medication mode cohorts were established, retrospective data collection and prospective follow-up were conducted on all subjects, and efficacy evaluation modeling was carried out for the grouped populations. The correlation between the data generated by different numbers of visits was fully considered, and an evaluation model that can dynamically evaluate the efficacy of patients was established, so as to achieve real-time, dynamic and accurate evaluation of the clinical efficacy of TCM, and predict the long-term prognosis, so as to provide a real-world evidence-based basis for guiding clinical practice and health policy formulation. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is a block diagram of a system for evaluating the efficacy of traditional Chinese medicine intervention for angina pectoris.

[0025] Figure 2 This is a flow chart of a method for evaluating the efficacy of traditional Chinese medicine intervention in angina pectoris. DETAILED DESCRIPTION

[0026] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0027] Embodiment 1:

[0028] The S01 case collection module collects information on hospitalized patients with phlegm-stasis syndrome who are clinically diagnosed with UA and creates files for each patient;

[0029] The S02 medication mode cohort module groups each patient's file information according to multiple selected TCM medication modes as exposure factors, and establishes different medication mode cohorts;

[0030] The S03 traceability collection module collects patients’ medical history characteristics, clinical diagnosis, comorbidities, treatment status, and length of hospital stay;

[0031] The S04 tracking and collection module followed up the patients and collected the primary and secondary outcome indicators, with the density of cardiovascular-related disease readmission as the primary outcome indicator, and the density of major adverse cardiovascular events (MACE), the density of all-cause mortality, the score of the TCM efficacy evaluation scale for different syndromes of coronary heart disease, the score of the Seattle Angina Scale (SAQ), and the GRACE score as secondary outcome indicators;

[0032] The S05 efficacy evaluation module combines the parameters of the tracing collection module and the tracking collection module to establish an efficacy evaluation model. The efficacy evaluation module uses the RNN algorithm to model the efficacy evaluation of grouped populations based on classic multivariate analysis, COX regression, and survival analysis.

[0033] Embodiment 2:

[0034] The S01 case collection module collects information on hospitalized patients with phlegm-stasis syndrome who are clinically diagnosed with UA and creates files for each patient;

[0035] The S02 medication mode cohort module groups each patient's file information according to multiple selected TCM medication modes as exposure factors, and establishes different medication mode cohorts;

[0036] The S03 traceability collection module collects patients’ medical history characteristics, clinical diagnosis, comorbidities, treatment status, and length of hospital stay;

[0037] The S04 tracking and collection module follows up on patients and collects primary and secondary outcome indicators, with the density of cardiovascular-related disease readmission as the primary outcome indicator, and the density of major adverse cardiovascular events (MACE), the density of all-cause mortality, the score of the Chinese medicine efficacy evaluation scale for different syndromes of coronary heart disease, the score of the Seattle Angina Scale (SAQ), and the GRACE score as secondary outcome indicators. The tracking and collection module also collects safety indicators, with the incidence of adverse events, liver function, kidney function, and coagulation as safety indicators;

[0038] The S05 efficacy evaluation module combines the parameters of the tracing collection module and the tracking collection module to establish an efficacy evaluation model. The efficacy evaluation module uses the RNN algorithm to model the efficacy evaluation of grouped populations based on classic multivariate analysis, COX regression, and survival analysis.

[0039] A two-way cohort study design was adopted. Based on the "chest pain and heart pain database", hospitalized patients with phlegm and blood stasis syndrome (about 4,000 cases) clinically diagnosed as UA were collected. They were grouped according to the exposure factors of multiple selected traditional Chinese medicine medication patterns, and cohorts with different medication patterns were established. Retrospective data collection and prospective follow-up were performed on all subjects. The follow-up period was 1 year, and the density of cardiovascular-related disease readmission was the main outcome indicator. The density of major adverse cardiovascular events (MACE), the density of all-cause mortality, the score of the TCM efficacy evaluation scale for different syndromes of coronary heart disease, and the Seattle Angina Scale were used as the indicators of clinical outcome. The SAQ score and GRACE score were used as secondary outcome indicators, and the incidence of adverse events, liver function, kidney function, and coagulation were used as safety indicators. Based on classical multivariate analysis, COX regression, and survival analysis, the RNN algorithm was used to model the efficacy evaluation of the grouped population. The correlation between the data generated by different numbers of visits was fully considered, and an evaluation model that can dynamically evaluate the efficacy of patients was established. The real-time, dynamic, and accurate evaluation of the clinical efficacy of traditional Chinese medicine was achieved, and the long-term prognosis was predicted, providing a real-world evidence-based basis for guiding clinical practice and health policy formulation.

[0040] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A therapeutic effect evaluation system for Chinese medicine intervention on angina pectoris, characterized in that: include: The case collection module collects information on hospitalized patients with phlegm-stasis syndrome who are clinically diagnosed with UA and creates files for each patient; The medication mode cohort module groups each patient according to their profile information and multiple selected TCM medication modes as exposure factors, and establishes different medication mode cohorts; The retrospective collection module collects the patient's medical history characteristics, clinical diagnosis, comorbidities, treatment status, and length of hospital stay; The tracking and collection module follows up the patients and collects the primary and secondary outcome indicators; The efficacy evaluation module combines the parameters of the tracing collection module and the tracking collection module to establish an efficacy evaluation model.

2. A therapeutic effect evaluation system for Chinese medicine intervention of angina pectoris according to claim 1, characterized in that: The density of readmission for cardiovascular-related diseases was the primary outcome indicator, and the density of major adverse cardiovascular events (MACE), the density of all-cause mortality, the scores of the Traditional Chinese Medicine Therapeutic Effect Evaluation Scale for different syndromes of coronary heart disease, the scores of the Seattle Angina Scale (SAQ), and the GRACE score were the secondary outcome indicators.

3. A therapeutic effect evaluation system for Chinese medicine intervention of angina pectoris according to claim 2, characterized in that: The tracking and collection module also collects safety indicators, with the incidence of adverse events, liver function, kidney function, and coagulation as safety indicators.

4. The therapeutic effect evaluation system of traditional Chinese medicine intervention for angina pectoris according to claim 1, characterized in that: The efficacy evaluation module uses the RNN algorithm to model the efficacy evaluation of grouped populations based on classic multivariate analysis, COX regression, and survival analysis.

5. A method for evaluating the efficacy of traditional Chinese medicine intervention for angina pectoris according to any one of claims 1 to 4, characterized in that: The steps include: 1) The case collection module collects information on hospitalized patients with phlegm-stasis syndrome clinically diagnosed as UA and creates files for each patient; 2) The medication mode cohort module groups each patient according to their profile information and multiple preferred TCM medication modes as exposure factors, and establishes different medication mode cohorts; 3) The retrospective collection module collects the patient's medical history characteristics, clinical diagnosis, comorbidities, treatment status, and length of hospital stay; 4) The tracking and collection module follows up patients and collects primary and secondary outcome indicators; 5) The efficacy evaluation module combines the parameters of the tracing collection module and the tracking collection module to establish an efficacy evaluation model.

Images